Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $74.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price lifted by Morgan Stanley from $67.00 to $74.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective suggests a potential upside of 192.26% from the company’s previous close.

Other research analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Monday, August 10th. Royal Bank Of Canada boosted their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Wedbush dropped their target price on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 9th. Finally, Wall Street Zen raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $58.89.

Ultragenyx Pharmaceutical Stock Down 3.5%

RARE stock opened at $25.32 on Friday. The business’s fifty day simple moving average is $28.55 and its two-hundred day simple moving average is $24.97. Ultragenyx Pharmaceutical has a twelve month low of $18.29 and a twelve month high of $39.89. The firm has a market cap of $2.50 billion, a price-to-earnings ratio of -4.34 and a beta of 0.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($1.22) by $0.32. The business had revenue of $214.00 million during the quarter, compared to the consensus estimate of $183.08 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The business’s revenue for the quarter was up 28.5% compared to the same quarter last year. During the same period last year, the company earned ($1.17) earnings per share. Research analysts expect that Ultragenyx Pharmaceutical will post -4.12 EPS for the current year.

Insider Activity

In other news, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $25.05, for a total transaction of $50,100.00. Following the transaction, the director owned 21,095 shares in the company, valued at approximately $528,429.75. This trade represents a 8.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Howard Horn sold 4,653 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $23.77, for a total transaction of $110,601.81. Following the completion of the sale, the chief financial officer directly owned 105,689 shares of the company’s stock, valued at approximately $2,512,227.53. This trade represents a 4.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 8,552 shares of company stock worth $207,455. Company insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several hedge funds have recently modified their holdings of RARE. BlackRock Inc. bought a new position in Ultragenyx Pharmaceutical in the second quarter worth approximately $355,746,000. Assenagon Asset Management S.A. boosted its position in Ultragenyx Pharmaceutical by 1,030.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company’s stock valued at $47,298,000 after acquiring an additional 2,057,951 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its position in Ultragenyx Pharmaceutical by 614.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock valued at $65,205,000 after acquiring an additional 1,864,164 shares in the last quarter. Norges Bank purchased a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at $29,004,000. Finally, Bank of America Corp DE purchased a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at $38,347,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: GENGLYCOS could expand Ultragenyx’s commercial pipeline and reduce the treatment burden for patients with GSDIa. The approval also included a Priority Review Voucher, which may have significant strategic or financial value. Reuters FDA approval report
• Positive Sentiment: The FDA decision strengthens Ultragenyx’s rare-disease portfolio and creates the potential for a long-term revenue contribution, which Wells Fargo described as a possible “long revenue tailwind.” Yahoo Finance gene-therapy analysis
• Positive Sentiment: Analysts responded favorably: Cantor Fitzgerald raised its price target to $103, Canaccord Genuity to $83, Citi to $58, and Wells Fargo to $46. Cantor, Canaccord, and Citi maintained or initiated “buy” or “overweight” ratings, implying substantial upside from the supplied $25.32 reference price.
• Neutral Sentiment: The accelerated approval is an important regulatory milestone, but commercial success will depend on launch execution, patient uptake, reimbursement, and any required confirmatory evidence. Ultragenyx remains unprofitable, with analysts expecting a full-year loss.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.